ERAS

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law

ERAS Faces Securities Class Action Over ERAS-0015 Data

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ERAS faces a securities class action alleging misstatements about ERAS-0015 data and a patent risk tied to Revolution Medicines. The class period runs January 14, 2025 to April 26, 2026, with lead plaintiff deadline August 10, 2026. The filing could keep ERAS in headlines and weigh sentiment until facts about the data claims are clarified.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Schall, Brown &amp; Schwartz reminds ERAS investors of class action. Lead plaintiff deadline Aug 10, 2026.</li><li>Case alleges ERAS misled on ERAS-0015 data. Improper Revolution Medicines comparison cited.</li><li>Class period: January 14, 2025 to April 26, 2026.</li><li>Lead plaintiff appointment not required. Contact details provided.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Erasca, Inc. (ERAS)</strong>: Subject of a securities-class action alleging misstatements.</li><li><strong>Revolution Medicines, Inc. (RML)</strong>: Referenced as comparator for ERAS-0015 data; potential IP scrutiny.</li><li><strong>Schall, Brown &amp; Schwartz LLP (N/A)</strong>: Plaintiff counsel; signals ongoing litigation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category Type: Legal. The piece centers on securities litigation and its potential impact on ERAS&#039;s valuation and disclosures.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal risk could pressure ERAS shares as investors reassess data disclosures.</li><li>Deadline August 10, 2026 creates a defined near-term uncertainty window.</li><li>Revolution Medicines comparison cited; raises IP/data-claims scrutiny.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class period: January 14, 2025 to April 26, 2026.</li><li>Deadline for lead plaintiff: August 10, 2026.</li><li>Lawsuit alleges violations of Section 10(b) and Rule 10b-5.</li><li>ERAS-0015 data cited as improper comparison to Revolution Medicines.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term on litigation risk; potential relief if the case progresses without material damages within 1–3 months.</p>
  </section>
</section>


<article>
  <section>
    <h2>ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law</h2>
    <p>LOS ANGELES, Aug.  03, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=TzqXxbaTboft0ychWPbjjDs6XIYzVwn0q4JSpfD-1qCPVqtNX2AftHbvVKTNEJMWTzQBamzXhHX7xnD6SPYWGkcXnijdIN2xnmRZ_B0Oh-rafTfP-Eru-aG5zTUy45R_" rel="nofollow" target="_blank">Schall, Brown &amp; Schwartz LLP</a> ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
    <p>Shareholders who purchased shares of ERAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.</p>
    <ul>
      <li><strong>CLASS PERIOD:</strong> January 14, 2025 to April 26, 2026</li>
      <li><strong>DEADLINE:</strong> August 10, 2026</li>
    </ul>
  </section>

  <section>
    <h3>Participation Details for ERAS Investors</h3>
    <p>If you are a shareholder who suffered a loss, <a href="https://www.globenewswire.com/Tracker?data=ztOV-IyaYTEjX17nJY4wv-42pIslWz5fCJBQgIQZd-EQJ_SNckOgu7BTlAivzI6utqPh86ykWl8bR6_ochuH1Ei9OoxY2ieaZRllqeaC9VbV19Fj2NC_Aspl9Pp6uot0" rel="nofollow" target="_blank">click here to participate</a>.</p>
    <p><strong>CASE DETAILS:</strong> According to the Complaint, the Company made false and misleading statements to the market. Erasca’s Preclinical data on ERAS-0015 was built on an improper comparison to Revolution Medicines, Inc., which placed it at risk of violating patent protections. The Company lacked basis for its optimistic statements on ERAS-0015. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Erasca, investors suffered damages.</p>
  </section>

  <section>
    <h3>Important Actions and How to Reach Counsel</h3>
    <p>We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown &amp; Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=fAaL2CHTlzFF_SD7YWFA4eDuJNy6enInMGx64JuovzZhYUGPxNS2x3o-9twKis_oqOKp_Fevift0iuUbyxiA5ebwRLdi7mgTfySXhwTBq6E=" rel="nofollow" target="_blank"><u>www.schallfirm.com</u></a>, or by email at <a href="https://www.globenewswire.com/Tracker?data=SUg5_jZjmDTaNIwB78uhnrDjn3YhZyufF5KZgLNJhRkNAOZq1tdTjxNTPvGlzCDBKl9_sovfc-eYy8yRK5c2TWgOT4W9eFcUH8nhfjv9h7E=" rel="nofollow" target="_blank">david@schallfirm.com</a>.</p>
    <p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
    <p><a href="https://www.globenewswire.com/Tracker?data=jT9RgCKE-iHK4mzxKXS-G13CqoYoTdLFedFnTffN_T6OWbFvFjpa57chPuF7M6F_tg7FTLPjAX4J2QUINfeGOV3PQXFm2nlMZwY3cyKipTnUBJMwYSBz0tE0V0OS7I83" rel="nofollow" target="_blank">Join the case</a> to recover your losses</p>
  </section>

  <section>
    <h3>Why SBS?</h3>
    <p><strong>WHY SBS?</strong> Schall, Brown &amp; Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.</p>
    <p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
  </section>

  <section>
    <h3>Contact and Source</h3>
    <p><strong>CONTACT:</strong></p>
    <p>Schall, Brown &amp; Schwartz LLP<br/>
      Brian Schall, Esq.,<br/>
      Andrew Brown, Esq.,<br/>
      David Schwartz, Esq.,<br/>
      <a href="https://www.globenewswire.com/Tracker?data=fAaL2CHTlzFF_SD7YWFA4Shg7uHzhoPfIdj2MewUBNlttAiQWP2Bnd45n44Dmnnkq09igOUBCyfxmPpUUTEOVwzTGulg9hEZ8to1EGURLcQ=" rel="nofollow" target="_blank">www.schallfirm.com</a><br/>
      Office: 310-301-3335<br/>
      <a href="https://www.globenewswire.com/Tracker?data=sHQkjfELcsyHvGMRbdBDjMW7Tm0F5QWhqiKsqeZygJbaPMwr_ACPXImMvCdoQstC-OUtgGuZ7vPDZXAREbO-oUb8X1m2Qhi10mjFljzlQFA=" rel="nofollow" target="_blank"><u>info@schallfirm.com</u></a></p>
    <p><strong>SOURCE:</strong></p>
    <p><strong> Schall, Brown &amp; Schwartz LLP</strong></p>
  </section>
</article>

ERAS faces a securities class action alleging misstatements about ERAS-0015 data and a patent risk tied to Revolution Medicines. The class period runs January 14, 2025 to April 26, 2026, with lead plaintiff deadline August 10, 2026. The filing could keep ERAS in headlines and weigh sentiment until facts about the data claims are clarified.

News insight

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law

AI summary

Sentiment rationale

Key facts

Legal